Nivolumab-IRDye800

DRUG2 trials

Sponsors

Eben Rosenthal, Vanderbilt-Ingram Cancer Center

Conditions

Brain CancerGliomaHGGHNSCCHigh Grade GliomaHigh Grade Glioma (HGG) of the Brain With BRAF AberrationHigh Grade Glioma (III or IV)High Grade Gliomas

Early Phase 1

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

RecruitingNCT07210632

Eben RosenthalBrain Cancer, Glioma, HGG +4

Start: 2026-03-27End: 2031-03-30Target: 38Updated: 2026-07-01

Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruitingNCT07741565

Vanderbilt-Ingram Cancer CenterHNSCC, Oral Cancer, SCC - Squamous Cell Carcinoma

Start: 2026-09-30End: 2031-09-30Target: 18Updated: 2026-08-03